BiotechTube

Trametinib + Paclitaxel

Phase 1Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic Thyroid Cancer

Conditions

Anaplastic Thyroid Cancer

Trial Timeline

Mar 15, 2017 → Sep 1, 2026

NCT ID
NCT03085056

About Trametinib + Paclitaxel

Trametinib + Paclitaxel is a phase 1 stage product being developed by Novartis for Anaplastic Thyroid Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03085056. Target conditions include Anaplastic Thyroid Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03085056Phase 1Active

Competing Products

20 competing products in Anaplastic Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
Lenvatinib 24 mgEisaiPhase 2
52
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
52
durvalumab + tremelimumabAstraZenecaPhase 1
33
PembrolizumabMerckPhase 2
52
LDK378 + AUY922NovartisPhase 1
33
ceritinibNovartisPre-clinical
23
LDK378NovartisPhase 1
33
CeritinibNovartisPhase 2
52
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
33
dabrafenib/trametinibNovartisPhase 2
52
Alectinib + CrizotinibRochePhase 3
77
Sunitinib MalatePfizerPhase 2
51
Crizotinib (PF-02341066)PfizerPhase 2
51
LorlatinibPfizerPhase 2
51
CrizotinibPfizerPhase 1/2
40
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
32
Etirinotecan pegolNektar TherapeuticsPhase 2
47
BevacizumabNovocurePhase 2
47

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85